INO – Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.INO
$1.10Name : Inovio Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $90,500,568.00
EPSttm : -1.59
Inovio Pharmaceuticals, Inc.
$1.10
0.92%$0.01
INO — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
19.52
Margin Of Safety %
Put/Call OI Ratio
0.02
EPS Next Q Diff
0.04
EPS Last/This Y
0.72
EPS This/Next Y
0.61
Price
1.11
Target Price
5.86
Analyst Recom
1.8
Performance Q
-36.42
Upside
-5,540.9%
Beta
1.49
Ticker: INO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | INO | 1.42 | 0.03 | 0.06 | 67138 |
| 2026-05-12 | INO | 1.415 | 0.04 | 0.02 | 70952 |
| 2026-05-13 | INO | 1.36 | 0.04 | 0.01 | 71835 |
| 2026-05-14 | INO | 1.365 | 0.03 | 0.06 | 77709 |
| 2026-05-15 | INO | 1.3 | 0.03 | 0.03 | 77815 |
| 2026-05-18 | INO | 1.225 | 0.03 | 0.02 | 64842 |
| 2026-05-19 | INO | 1.22 | 0.03 | 0.01 | 65468 |
| 2026-05-20 | INO | 1.23 | 0.03 | 0.06 | 70894 |
| 2026-05-21 | INO | 1.34 | 0.02 | 0.01 | 71058 |
| 2026-05-22 | INO | 1.36 | 0.02 | 0.01 | 74340 |
| 2026-05-26 | INO | 1.275 | 0.02 | 0.00 | 71501 |
| 2026-05-27 | INO | 1.255 | 0.02 | 0.04 | 75591 |
| 2026-05-28 | INO | 1.305 | 0.02 | 0.01 | 75794 |
| 2026-05-29 | INO | 1.32 | 0.02 | 0.06 | 78348 |
| 2026-06-02 | INO | 1.215 | 0.02 | 0.05 | 81426 |
| 2026-06-03 | INO | 1.145 | 0.02 | 0.00 | 81435 |
| 2026-06-04 | INO | 1.16 | 0.02 | 0.02 | 81574 |
| 2026-06-05 | INO | 1.06 | 0.02 | 0.04 | 81613 |
| 2026-06-08 | INO | 1.09 | 0.02 | 0.02 | 79264 |
| 2026-06-09 | INO | 1.105 | 0.02 | 0.01 | 79510 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | INO | 1.42 | 36.0 | - | -1.04 |
| 2026-05-12 | INO | 1.41 | 36.0 | - | -1.04 |
| 2026-05-13 | INO | 1.36 | 36.0 | - | -1.04 |
| 2026-05-14 | INO | 1.37 | 36.0 | - | -1.04 |
| 2026-05-15 | INO | 1.30 | 36.0 | - | -1.04 |
| 2026-05-18 | INO | 1.23 | 36.0 | - | -1.04 |
| 2026-05-19 | INO | 1.22 | 36.0 | - | -1.04 |
| 2026-05-20 | INO | 1.24 | 62.3 | - | -1.04 |
| 2026-05-21 | INO | 1.34 | 62.3 | - | -1.04 |
| 2026-05-22 | INO | 1.36 | 55.3 | - | -1.04 |
| 2026-05-26 | INO | 1.27 | 55.3 | - | -1.04 |
| 2026-05-27 | INO | 1.26 | 55.3 | - | -1.04 |
| 2026-05-28 | INO | 1.30 | 55.3 | - | -1.04 |
| 2026-05-29 | INO | 1.32 | 55.3 | - | -1.04 |
| 2026-06-01 | INO | 1.29 | 55.3 | - | -1.10 |
| 2026-06-02 | INO | 1.21 | 55.3 | - | -1.10 |
| 2026-06-03 | INO | 1.14 | 55.3 | - | -1.10 |
| 2026-06-04 | INO | 1.16 | 55.3 | - | -1.10 |
| 2026-06-05 | INO | 1.07 | 56.2 | - | -1.09 |
| 2026-06-08 | INO | 1.10 | 56.2 | - | -1.09 |
| 2026-06-09 | INO | 1.11 | 56.2 | - | -1.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | INO | 0.00 | 2.28 | 15.66 |
| 2026-05-12 | INO | 0.00 | 2.28 | 17.46 |
| 2026-05-13 | INO | 0.00 | 2.28 | 17.46 |
| 2026-05-14 | INO | 0.00 | 2.28 | 17.46 |
| 2026-05-15 | INO | 0.00 | 2.28 | 17.46 |
| 2026-05-18 | INO | 0.00 | 1.59 | 17.45 |
| 2026-05-19 | INO | 0.00 | 1.59 | 17.45 |
| 2026-05-20 | INO | 0.00 | 1.59 | 17.45 |
| 2026-05-21 | INO | 0.00 | 1.59 | 17.45 |
| 2026-05-22 | INO | 0.00 | 1.59 | 17.45 |
| 2026-05-26 | INO | 0.00 | -2.04 | 17.39 |
| 2026-05-27 | INO | 0.00 | -2.04 | 17.39 |
| 2026-05-28 | INO | 0.00 | -2.04 | 19.52 |
| 2026-05-29 | INO | 0.00 | -2.04 | 19.52 |
| 2026-06-02 | INO | 0.00 | -2.53 | 19.52 |
| 2026-06-03 | INO | 0.00 | -2.53 | 19.52 |
| 2026-06-04 | INO | 0.00 | -2.53 | 19.52 |
| 2026-06-05 | INO | 0.00 | -2.53 | 19.52 |
| 2026-06-08 | INO | 0.00 | -2.53 | 19.52 |
| 2026-06-09 | INO | 0.00 | -2.53 | 19.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.28
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.24
Insider Transactions
Institutional Transactions
-2.53
Beta
1.49
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
2
Growth Score
23
Sentiment Score
16
Actual DrawDown %
99.1
Max Drawdown 5-Year %
-99.1
Target Price
5.86
P/E
Forward P/E
PEG
P/S
P/B
12.65
P/Free Cash Flow
EPS
-1.71
Average EPS Est. Cur. Y
-1.09
EPS Next Y. (Est.)
-0.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.43
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
◆
INO
Healthcare
$1.10
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
38.7
Range 1M
7%
Sup Dist
2.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
51.3%
EPS NY
51.1%
52W%
3.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+432.7% upside
Upside
+432.7%
Quality
2
Inovio Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 112
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
INO
Latest News
—
Caricamento notizie per INO…
stock quote shares INO – Inovio Pharmaceuticals, Inc. Stock Price stock today
news today INO – Inovio Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch INO – Inovio Pharmaceuticals, Inc. yahoo finance google finance
stock history INO – Inovio Pharmaceuticals, Inc. invest stock market
stock prices INO premarket after hours
ticker INO fair value insiders trading